These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 725844

  • 21. Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes--a multicentre trial.
    Latallo ZS.
    Thromb Haemost; 1983 Aug 30; 50(2):604-9. PubMed ID: 6227104
    [No Abstract] [Full Text] [Related]

  • 22. [Therapeutic effect of blood viscosity in stroke].
    Heiss WD.
    Beitr Infusionther Klin Ernahr; 1981 Aug 30; 8():22-32. PubMed ID: 6172108
    [No Abstract] [Full Text] [Related]

  • 23. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
    Dempfle CE, Alesci S, Kucher K, Müller-Peltzer H, Rübsamen K, Borggrefe M.
    Thromb Res; 2001 Dec 15; 104(6):433-8. PubMed ID: 11755954
    [Abstract] [Full Text] [Related]

  • 24. The importance of plasma fibrinogen in vascular surgery.
    Postlethwaite JC.
    Ann R Coll Surg Engl; 1976 Nov 15; 58(6):457-64. PubMed ID: 984690
    [Abstract] [Full Text] [Related]

  • 25. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
    McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM.
    Clin Lab Sci; 2007 Nov 15; 20(2):99-105. PubMed ID: 17557708
    [Abstract] [Full Text] [Related]

  • 26. Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke.
    Elger B, Laux V, Schwarz M.
    Arzneimittelforschung; 1997 Aug 15; 47(8):895-9. PubMed ID: 9296273
    [Abstract] [Full Text] [Related]

  • 27. [Thrombotic arterial and venous obstructions under ancrod (Arwin) therapy (author's transl)].
    Heidrich H.
    Med Klin; 1978 May 26; 73(21):798-800. PubMed ID: 651769
    [Abstract] [Full Text] [Related]

  • 28. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP.
    Thromb Haemost; 1994 May 26; 71(5):558-62. PubMed ID: 8091380
    [Abstract] [Full Text] [Related]

  • 29. Prevention of deep vein thrombosis by subcutaneous ancrod.
    Lowe GD.
    Scott Med J; 1978 Oct 26; 23(4):329-30. PubMed ID: 364647
    [No Abstract] [Full Text] [Related]

  • 30. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb 26; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 31. An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery.
    Poller L, Taberner DA, Sandilands DG, Galasko CS.
    Thromb Haemost; 1982 Feb 26; 47(1):50-3. PubMed ID: 7071805
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
    Akanmu AS, Nnodu OE, Giwa SO, Salako LA, Akinsete I, Adebule GT, Adekoya-Cole TO, Odunubi OO.
    Afr J Med Med Sci; 2004 Dec 26; 33(4):335-40. PubMed ID: 15977441
    [Abstract] [Full Text] [Related]

  • 33. Ancrod causes rapid thrombolysis in patients with acute stroke.
    Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA.
    Am J Med Sci; 1990 May 26; 299(5):319-25. PubMed ID: 2186630
    [Abstract] [Full Text] [Related]

  • 34. Ancrod in the treatment of acute ischaemic stroke.
    Atkinson RP.
    Drugs; 1997 May 26; 54 Suppl 3():100-8. PubMed ID: 9360857
    [Abstract] [Full Text] [Related]

  • 35. [Relations between the concentration of fibrinogen, thromboplastin time, thrombin time and reptilase time in patients treated with Arwin].
    Paar D, Klüken N.
    Med Welt; 1975 Sep 19; 26(38):1700-1. PubMed ID: 1186461
    [No Abstract] [Full Text] [Related]

  • 36. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
    Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P, Halmosi R, Papp E, Juricskay I.
    Clin Hemorheol Microcirc; 1999 Sep 19; 21(3-4):209-16. PubMed ID: 10711745
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
    Simpson PJ, Schelm JA, Smith GF.
    J Pharmacol Exp Ther; 1991 Feb 19; 256(2):780-6. PubMed ID: 1704437
    [Abstract] [Full Text] [Related]

  • 38. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV, Schwartz ML, Hill RL, McKee PA.
    J Clin Invest; 1972 Nov 19; 51(11):2841-50. PubMed ID: 4263497
    [Abstract] [Full Text] [Related]

  • 39. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 19; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 40. Treatment of severe intermittent claudication by controlled defibrination.
    Dormandy JA, Goyle KB, Reid HL.
    Lancet; 1977 Mar 19; 1(8012):625-6. PubMed ID: 66429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.